27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
We included 147,986 participants (Chinese [n = 6,034], Filipino [n = 4,649], Japanese [n = 3,099], South Asian [n = 996], non-Latino White [n = 133,208]); the mean baseline age ranged from 69 to 72 years, and the percentage of female participants ranged from 40% to 63% across groups. 5 key findings →
Design: cohort study Participants: 6,034 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Blood phosphorylated (p)-tau 181 and p-tau 217 have been proposed as accurate biomarkers of Alzheimer's disease (AD) pathology. 2 key findings →
Participants: 152 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer's disease. 3 key findings →
Participants: 392 Evidence: low
Full summary, score breakdown and related studies → Original source
BackgroundDiabetes has been linked to increased prevalence of dementia, but the link between diabetic retinopathy (DR) and Alzheimer's disease (AD) remains unclear. 4 key findings →
Design: cross-sectional Participants: 79 Evidence: low
Full summary, score breakdown and related studies → Original source
The study included 44 iRBD patients (81.8% males, mean age 71.0 ± 6.4 years), 55 HC (66.3% males, mean age 69.1 ± 5.5 years), and 28 AD patients (82.1% males, mean age of 70.4 ± 6.7 years). iRBD patients showed significantly higher plasma NfL and GFAP levels and similar pTau181 levels compared to HC. 5 key findings →
Design: cross-sectional Participants: 44 Evidence: low
Full summary, score breakdown and related studies → Original source
The data of 1734 participants (1158 with AD, 105 with DLB, 46 with VaD, and 425 with CN) were analyzed. 4 key findings →
Design: cross-sectional Participants: 1,734 Evidence: low
Full summary, score breakdown and related studies → Original source
Tau positivity was found in 90% of CBS cases, Aβ in 28%, and αSyn in 24%. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 1005 amyloid-positive participants, 24.6% were eligible for lecanemab and 28.0% for donanemab (9.1% and 10.3% of the initial sample). 5 key findings →
Participants: 2,726 Evidence: low
Full summary, score breakdown and related studies → Original source
Our two-sample MR analysis indicated that T2D is not associated with the risk of AD (OR: 1.03, CI: 0.99-1.08, P = 0.128). 5 key findings →
Participants: 455,017 Evidence: low
Full summary, score breakdown and related studies → Original source
The gut-brain axis explains that changes in the intestinal microbiota influence Alzheimer's disease (AD). 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The mean age of the patients was 73.1 ± 11.7, and the time since diagnosis was 3.9 ± 3.1 years; 64.8% had Alzheimer's type dementia, and 53.4% (n = 47) had mild dementia. 5 key findings →
Design: cross-sectional Participants: 47 Evidence: low
Full summary, score breakdown and related studies → Original source
This paper reports first-year, real-world results from one of the 96 'Established Track' organizations in the CMS GUIDE dementia care model, which launched nationally on July 1, 2024. 5 key findings →
Design: cohort Participants: 158 Evidence: early
Full summary, score breakdown and related studies → Original source
In this national case-control study of nursing home residents with ADRD receiving hospice care, initiation of benzodiazepine or antipsychotic use was associated with increased 180-day mortality. 5 key findings →
Design: case-control Participants: 139,103 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The majority of participants were female and were taking concomitant psychotropic medications (antidepressants and antipsychotics) at baseline. 3 key findings →
Design: phase-2-trial Participants: 75 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
A distinct set of midlife depressive symptoms was associated with an increased risk of dementia, suggesting that these symptoms might be early markers of underlying neurodegenerative processes. 4 key findings →
Design: cohort Participants: 5,811 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
EOAD, although sharing genes with LOAD, harbors unique genes and pathways that could be used to create better prediction models or target identification. 2 key findings →
Design: case-control Participants: 25,236 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
As the brain transitions from wakefulness to sleep, processing of external information diminishes while restorative processes, such as glymphatic removal of waste products, are activated. 5 key findings →
Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
Our findings suggest that poor olfaction is associated with multiple AD-related and other neurodegenerative processes. 5 key findings →
Design: cross-sectional Participants: 1,545 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among adults with Down syndrome, the striatum consistently accumulates amyloid earlier than the cortex when measured with PiB. 2 key findings →
Design: longitudinal study Participants: 175 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The aim of this study was to evaluate longitudinal associations of multimodal core 1 AD biomarkers with cognition in a cognitively unimpaired (CU) population at increased risk of AD dementia. 4 key findings →
Design: longitudinal study Participants: 350 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The mean age of participants was 77.1 years (SD = 7.6), and 2779 were women (weighted % = 56.7). 4 key findings →
Design: cohort study Participants: 1,238 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The sample included 740 donors (417 female [56.4%]; mean [SD] age at death, 81.5 [10.3] years; mean [SD] VBI score, 0.7 [1.0]; and median life course ADI, 7.08 [IQR, 4.33-9.83]), with residential years spanning 1905 to 2018. 5 key findings →
Design: cohort study Participants: 740 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 463 ADNI participants with baseline MCI (mean age 72.6 ± 7.3 years, 43.4% female), the OSA PRS, adjusted for BMI, was significantly associated with MCI-to-AD progression. 5 key findings →
Design: prospective cohort Participants: 752 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 809 participants (mean [SD] age at death, 91.3 [6.1] years; 538 [72%] female; mean [SD] follow-up, 7.2 [4.4] years), HS was present in 82 (10.1%) participants; 71 participants (9%) had both HS and LATE-NC, and in the scored subset, 43 participants (14%) had moderate and 35 participants (12%) had severe hippocampal neuronal loss. 5 key findings →
Design: cohort study Participants: 300 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Agriculture in Nigeria, Kenya, and Mali is impacted by droughts, necessitating resilient crops and improved irrigation. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →